Calithera Biosciences Management
Management criteria checks 3/4
Calithera Biosciences' CEO is Susan Molineaux, appointed in Mar 2010, has a tenure of 13.17 years. total yearly compensation is $817.30K, comprised of 74.6% salary and 25.4% bonuses, including company stock and options. directly owns 0.73% of the company’s shares, worth €852.31. The average tenure of the management team and the board of directors is 6.3 years and 7.2 years respectively.
Key information
Susan Molineaux
Chief executive officer
US$817.3k
Total compensation
| CEO salary percentage | 74.6% |
| CEO tenure | 13.2yrs |
| CEO ownership | 0.7% |
| Management average tenure | 6.3yrs |
| Board average tenure | 7.2yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2022 | US$817k | US$610k | -US$21m |
| Sep 30 2022 | n/a | n/a | -US$84m |
| Jun 30 2022 | n/a | n/a | -US$85m |
| Mar 31 2022 | n/a | n/a | -US$107m |
| Dec 31 2021 | US$2m | US$589k | -US$115m |
| Sep 30 2021 | n/a | n/a | -US$68m |
| Jun 30 2021 | n/a | n/a | -US$80m |
| Mar 31 2021 | n/a | n/a | -US$86m |
| Dec 31 2020 | US$4m | US$569k | -US$90m |
| Sep 30 2020 | n/a | n/a | -US$89m |
| Jun 30 2020 | n/a | n/a | -US$87m |
| Mar 31 2020 | n/a | n/a | -US$91m |
| Dec 31 2019 | US$2m | US$550k | -US$90m |
| Sep 30 2019 | n/a | n/a | -US$88m |
| Jun 30 2019 | n/a | n/a | -US$86m |
| Mar 31 2019 | n/a | n/a | -US$65m |
| Dec 31 2018 | US$2m | US$530k | -US$55m |
| Sep 30 2018 | n/a | n/a | -US$46m |
| Jun 30 2018 | n/a | n/a | -US$33m |
| Mar 31 2018 | n/a | n/a | -US$35m |
| Dec 31 2017 | US$761k | US$504k | -US$28m |
| Sep 30 2017 | n/a | n/a | -US$26m |
| Jun 30 2017 | n/a | n/a | -US$29m |
| Mar 31 2017 | n/a | n/a | -US$34m |
| Dec 31 2016 | US$2m | US$475k | -US$38m |
Compensation vs Market: Susan's total compensation ($USD817.30K) is above average for companies of similar size in the German market ($USD418.12K).
Compensation vs Earnings: Susan's compensation has been consistent with company performance over the past year.
CEO
Susan Molineaux (68 yo)
13.2yrs
Tenure
US$817,299
Compensation
Dr. Susan M. Molineaux, Ph D., She serves as President and Chief Executive Officer of Para Therapeutics Inc., a position she has held since April 2023. She serves as an Independent Director at Cyteir Thera...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 13.2yrs | US$817.30k | 0.73% $ 852.3 | |
| CFO & Secretary | 6.3yrs | US$821.32k | 0.12% $ 141.8 | |
| Senior Vice President of Development | 10.1yrs | US$446.60k | 0.76% $ 892.6 | |
| Senior Vice President of Research | no data | no data | no data | |
| Senior Vice President of R&D Operations | 1.3yrs | no data | no data | |
| Senior Vice President of Commercial & Portfolio Strategy | 1.3yrs | no data | no data |
6.3yrs
Average Tenure
60.5yo
Average Age
Experienced Management: 2CB0's management team is seasoned and experienced (6.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 13.2yrs | US$817.30k | 0.73% $ 852.3 | |
| Independent Director | 8.4yrs | US$57.95k | 0% $ 0 | |
| Lead Independent Director | 10.7yrs | US$91.81k | 0% $ 0 | |
| Independent Director | 7.7yrs | US$64.60k | 0% $ 0 | |
| Independent Director | 2.8yrs | US$62.45k | 0% $ 0 | |
| Independent Director | 6.8yrs | US$55.31k | 0.0074% $ 8.6 | |
| Director | 1.5yrs | US$60.43k | 0.0011% $ 1.3 | |
| Independent Director | 5.7yrs | US$54.45k | 0% $ 0 |
7.2yrs
Average Tenure
54.5yo
Average Age
Experienced Board: 2CB0's board of directors are considered experienced (7.2 years average tenure).